Arrowhead Pharmaceuticals, Inc. (ARWR)
| Market Cap | 11.13B +553.1% |
| Revenue (ttm) | 622.01M +14.1% |
| Net Income | -300.91M |
| EPS | -2.17 |
| Shares Out | 140.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,544,470 |
| Open | 76.88 |
| Previous Close | 77.74 |
| Day's Range | 76.62 - 79.67 |
| 52-Week Range | 13.42 - 80.27 |
| Beta | 1.29 |
| Analysts | Strong Buy |
| Price Target | 84.45 (+6.85%) |
| Earnings Date | May 7, 2026 |
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ... [Read more]
Financial Performance
In fiscal year 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ARWR stock is "Strong Buy." The 12-month stock price target is $84.45, which is an increase of 6.85% from the latest price.
News
Arrowhead price target raised to $90 from $80 at Chardan
Chardan raised the firm’s price target on Arrowhead (ARWR) to $90 from $80 and keeps a Buy rating on the shares post the fiscal Q2 report. The U.S. launch of…
Arrowhead reports Q2 EPS (93c), consensus ($1.11)
Reports Q2 revenue $73.7M, consensus $71.7M. “Arrowhead (ARWR) continues to show strong execution in meeting and exceeding our commercial, R&D, and corporate goals. The company is on extremely strong ...
Arrowhead Pharmaceuticals Earnings Call Transcript: Q2 2026
REDEMPLO's U.S. launch exceeded expectations, with strong prescription growth and positive payer feedback. Major pipeline milestones are expected in Q3/Q4 2026, and the company is well-funded after significant capital raises and a lucrative licensing deal with Madrigal.
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is ho...
Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma
Arrowhead Pharmaceuticals (ARWR) announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (MDGL) for ARO-PNPLA3, Arrowhead’s clinical stage RNA interference therapeutic designe...
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for AR...
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the events in which it is scheduled to participate throughout the month of May, 2026.
Arrowhead announces Australian TGA approved Redemplo for FCS
Arrowhead (ARWR) Pharmaceuticals announced that the Australian Therapeutic Goods Administration, TGA, has approved Redemplo, a small interfering RNA medicine, as an adjunct to diet to reduce triglycer...
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasira...
Arrowhead initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Arrowhead (ARWR) with an Overweight rating and $88 price target The company has a a “highly diversified” RNAi portfolio targeting a spectrum of diseases and is…
Arrowhead announces EMA recommended approval of Redemplo
Arrowhead (ARWR) Pharmaceuticals announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or EMA CHMP, has adopted a positive opinion, recommending the approval o...
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA CHM...
This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains.
Arrowhead Pharmaceuticals stock could build on its rally in the third quarter, Morgan Stanley says.
Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Arrowhead (ARWR) to Overweight from Equal Weight with a price target of $100, up from $78. The firm sees the stock’s momentum continuing ahead of Phase 3…
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 7, 2026, at 4:30 p.m. ET to discuss i...
Arrowhead price target raised to $93 from $81 at BofA
BofA raised the firm’s price target on Arrowhead (ARWR) to $93 from $81 and keeps a Buy rating on the shares. The firm’s raised target reflects a refined view of…
Arrowhead presents long-term efficacy, safety data for plozasiran
Arrowhead (ARWR) Pharmaceuticals announced long-term efficacy and safety data from a two-year long open-label extension, OLE, study of investigational plozasiran supporting its potential as therapeuti...
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of ...
Arrowhead price target lowered to $81 from $84 at BofA
BofA lowered the firm’s price target on Arrowhead (ARWR) to $81 from $84 and keeps a Buy rating on the shares. Arrowhead shares fell modestly on mixed competitor INHBE data,…
Arrowhead Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Multiple late-stage clinical readouts, including SHASTA-3/4 and first-in-class bispecific RNA data, are expected in Q3. Commercial focus is on high-risk populations, with innovation in delivery and dimer technology driving differentiation. Ex-US strategy adapts to pricing uncertainties, while platform expansion targets new tissues and CNS indications.
Arrowhead Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
The company is prioritizing cardiometabolic and CNS programs, with major data readouts for plozasiran and ARO-MAPT expected in 2026. Waylivra's launch for FCS has exceeded expectations, and the pipeline includes innovative obesity, liver, and lipid therapies, with a focus on premium pricing and strategic market positioning.
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen 46th Annual H...
Arrowhead price target lowered to $78 from $81 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Arrowhead (ARWR) to $78 from $81 and keeps an Equal Weight rating on the shares. Broad pipeline execution continues with multiple readouts…
Arrowhead Pharmaceuticals Earnings Call Transcript: Q1 2026
REDEMPLO received first approvals and launched in the U.S. with strong early uptake and positive payer feedback. Financials turned positive on $264M revenue, driven by licensing and milestones, and the balance sheet was significantly strengthened. Multiple late-stage readouts and launches are expected in 2026.
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 first quarter ended December 31, 2025. The Company is ...